Health
Portfolio conflict allegedLower drug prices with a well-positioned drug portfolio
The drug-price announcements have been good news for at least one portfolio.
- Executive owner
- Donald J. Trump / Independent Portfolio Management
- Status
- Portfolio conflict alleged
- Due
- Before the next pharmaceutical agreement
- Paying for it
- Medicare beneficiaries and public confidence
ACTIVITY
UpdatedThe portfolio increased its pharmaceutical allocation after the President returned to office.
I'm doing HISTORIC Price-Lowering, they can put that in very big letters..... if there's any nice letters left on their keyboards!
Congress exempted additional medications from Medicare price negotiations.
Reviewers identified holdings in companies benefiting from those exemptions.
I don't sit around picking Pills for a Portfolio!!
I DON'T RUN THE PORTFOLIO, they know it! Ask about Drug Prices for a change.
We bring down Drug Prices, they ask about Stocks. Stocks go down, Trump destroyed the Companies. They go UP, SCANDAL! See how this works?? You couldn't win with these people, unless you're me.
PUBLIC RECORD
A report from congressional Democrats says Trump’s pharmaceutical holdings rose from a maximum disclosed value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025. It identified investments in companies benefiting from Medicare negotiation exemptions. The White House says third-party institutions independently manage the portfolio and denies a conflict.